Live Breaking News & Updates on Tony bizuo liu

Stay informed with the latest breaking news from Tony bizuo liu on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Tony bizuo liu and stay connected to the pulse of your community

AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference

AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rockville , California , United-states , Maryland , Shanghai , China , Mission-bay , San-francisco , Tony-bizuo-liu , Sarah-kelly , Prnewswire-abelzeta-pharma-inc , Company-contact

AbelZeta to present company update at J.P. Morgan Healthcare Conference

AbelZeta to present company update at J.P. Morgan Healthcare Conference
thedailyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailyrecord.com Daily Mail and Mail on Sunday newspapers.

Tony-bizuo-liu , Abelzeta-pharma-inc , Zeta-pharma-inc , Healthcare-conference , Westin-san-francisco ,

CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc.

CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc.
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Maryland , United-states , Greece , Shanghai , China , Rockville , Greek , Sarah-kelly , Tony-bizuo-liu , Holdings-the-company , Abelzeta-pharma-inc , Company-contact

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

China , Chinese , Yusri-elsayed , Tony-bizuo-liu , Cellular-biomedicine-group , Janssen-research-development , Drug-administration , Janssen-pharmaceutical-companies-of-johnson , Janssen-pharmaceutical-companies , Greater-china , Janssen-research ,

Cellular Biomedicine Group Announces Exclusive Collaboration and License Agreement with Janssen to Develop and Commercialize anti CD19 & CD20 Bi-Specific and anti CD20 CAR-Ts for Non-Hodgkin Lymphoma

/PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the Company), a clinical-stage biopharmaceutical company focused on discovery and development of...

Shanghai , China , Sarah-kelly , Tony-bizuo-liu , Paula-silva , Cellular-biomedicine-group-inc , Company-contact , Drug-administration , Communications-investor-relations , Janssen-biotech-inc , Cellular-biomedicine-group , Janssen-biotech

FDA grants fast track, RMAT designations to bispecific CAR-T for non-Hodgkin lymphoma

The FDA granted fast track and regenerative medicine advanced therapy designations to C-CAR039, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory diffuse large B cell lymphoma.C-CAR039 (Cellular Biomedicine Group, CBMG) is an autologous, gene-edited, bispecific CAR T-cell therapy that targets both CD19 and CD20 proteins on the surface of cancer

China , Tony-bizuo-liu , Cellular-biomedicine-group , Century-cures-act ,

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

/PRNewswire/ -- Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the...

China , Rockville , Maryland , United-states , Tony-bizuo-liu , Sarah-kelly , Communications-investor-relations , Holdings , Company-contact , Drug-administration , Prnewswire-cellular-biomedicine-group-inc , Office-of-orphan-products-development

CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies

/PRNewswire/ -- CBMG Holdings (or the "Company"), a Cayman Island biopharmaceutical company developing innovative cellular immunotherapies for the treatment of...

China , Rockville , Maryland , United-states , Yunfeng , Sichuan , American , Tony-bizuo-liu , Sarah-kelly , Communications-investor-relations , American-society-of-clinical-oncology , Company-contact

CBMG Holdings' Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Early Promising Clinical Efficacy and Favorable Safety Profile in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ -- CBMG Holdings (or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine.
Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin's Lymphoma.

China , Rockville , Maryland , United-states , Tongji , Sichuan , American , Tony-bizuo-liu , Aibin-liang , Kaplan-meyer , Sarah-kelly , Communications-investor-relations

CBMG Holdings' Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Patients Following Relapse to an anti-CD19 CAR-T Therapy

Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ -- CBMG Holdings (or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China.

China , Rockville , Maryland , United-states , Tongji , Sichuan , Tianjin , American , Tony-bizuo-liu , Aibin-liang , Sarah-kelly , Communications-investor-relations